Skip to Content

Russell Inv Equity Income C REQSX

Medalist Rating as of | See Russell Investments Investment Hub
  • NAV / 1-Day Return 23.67  /  −0.13 %
  • Total Assets 190.4 Mil
  • Adj. Expense Ratio
    1.870%
  • Expense Ratio 1.870%
  • Distribution Fee Level Above Average
  • Share Class Type Level Load
  • Category Large Value
  • Investment Style Large Value
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.69%
  • Turnover 31%

USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:23 PM GMT+0

Morningstar’s Analysis REQSX

Will REQSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in Russell Inv Equity Income C's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings REQSX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 19.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

E-mini S&P 500 Future June 24

4.61 9.6 Mil

U.S. Cash Management Fund

4.40 9.1 Mil
Cash and Equivalents

JPMorgan Chase & Co

2.35 4.9 Mil
Financial Services

Berkshire Hathaway Inc Class B

2.00 4.1 Mil
Financial Services

CVS Health Corp

1.93 4.0 Mil
Healthcare

Wells Fargo & Co

1.63 3.4 Mil
Financial Services

Merck & Co Inc

1.57 3.2 Mil
Healthcare

Citigroup Inc

1.56 3.2 Mil
Financial Services

Johnson & Johnson

1.35 2.8 Mil
Healthcare

Medtronic PLC

1.32 2.7 Mil
Healthcare